Orthomolecular | Naturopathic Believer that our complete history is a lie | our past is more advanced than we know. Space | Nuclear | Gravity | Dinos=FAKE AMA!
🎆2026 https://t.co/5xo7LSIrN4 New Year Airdrop🎉
Snag your slice of 10,000 $ANB rewards by finishing a few quick tasks:
🔶Connect your X account and follow @ant_fun_trade
🔶Retweet our post
🔶Make your first trade on Web (0 fees!) or in the App
🔶Invite friends and earn extra bonuses
Event ends in 15 days, check the details on the event page.
Join now: https://t.co/YgHTiUmKnk
Fully Local Wallet Control + Multi-Chain All-in-One + Zero Platform Fee = Your Future Trading!
The following video demonstrates the above chan board post revealing Trump's traditional presidential battery salute compared to the above foreign dignitary salute for Joe Bidan.
💊 https://t.co/E09WrenLg7
https://t.co/oiP6nb4Bdr
The following video demonstrates the above chan board post revealing Joe Bidan's foreign dignitary salute which we will next compare to Trump's traditional presidential battery salute.
💊 https://t.co/E09WrenLg7
https://t.co/zVEnsfl5LM
@GeneralMCNews Everything is falling into place, the military used a shadow presidency BIDAN for the time being to hold everything over in the public view until it was time for public mass arrests and military tribunals.
Hope on the Horizon for Tooth Regrowth: USAG-1 Protein Blocker Enters Human Trials
A groundbreaking drug that blocks the USAG-1 protein, potentially enabling the regrowth of lost teeth, has entered its first phase of human clinical trials in 2024. This innovative therapy, developed by Japanese company Toregem Biopharma, offers a potential future alternative to traditional dental implants and dentures.
The treatment works by inhibiting the Uterine Sensitization Associated Gene-1 (USAG-1), a protein that naturally suppresses tooth development. By blocking this protein, the drug aims to unleash the body's latent potential to form new teeth. The underlying science is based on the discovery that individuals with a congenital deficiency in the USAG-1 gene often develop supernumerary, or extra, teeth.
The antibody-based drug, known as TRG-035, has demonstrated remarkable success in animal studies, inducing the growth of new teeth in mice, ferrets, and dogs without significant adverse effects. These promising preclinical results have paved the way for the current human trials.
The initial phase of the clinical trial is focused on assessing the safety and efficacy of the drug in healthy adults who are missing at least one tooth. If successful, the research will expand to include children with congenital tooth agenesis, a condition where multiple teeth fail to develop.
While the prospect of regrowing natural teeth is a significant advancement in dentistry, it is important to note that the research is still in its early stages. The timeline for this therapy to become widely available is projected to be around 2030, pending the successful completion of all clinical trial phases and regulatory approvals. The long-term goal for this treatment extends beyond congenital conditions to eventually include individuals who have lost teeth due to cavities, injury, or other acquired causes.